Literature DB >> 6130664

Intravenous benzodiazepines as anaesthetic agents: pharmacokinetics and clinical consequences.

J Kanto, U Klotz.   

Abstract

Despite extensive and numerous pharmacokinetic studies on benzodiazepines, the published pharmacokinetic data do not adequately explain the clinical differences found between different benzodiazepine derivatives after intravenous administration. Especially, correlations between initial drug responses and distributional changes of the benzodiazepines are limited. However, during the elimination phase some relationships exist between the kinetic and dynamic phenomena. Age, sex, diseases and concomitantly given drugs cause clinically important alterations in the pharmacokinetics of benzodiazepines. Generally these anxiolytics and sedatives should be considered as adjuvants to general anaesthesia, but not primarily as routine induction agents. The major reasons for this limitation are a high variability in drug response, a relatively slow onset of action and long-lasting residual effects. However, benzodiazepines have many important advantages (see Table 5) when used as intravenous inducing agents of general anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6130664     DOI: 10.1111/j.1399-6576.1982.tb01817.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  10 in total

Review 1.  Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

Authors:  B N Swerdlow; F O Holley
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

2.  Chronopharmacokinetic study with prolonged infusion of midazolam.

Authors:  U Klotz; I W Reimann
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

3.  Therapeutics and sedation in dentistry.

Authors:  E R Young
Journal:  Can Fam Physician       Date:  1988-06       Impact factor: 3.275

Review 4.  A comprehensive review of remimazolam for sedation.

Authors:  Nazir Noor; Rhorer Legendre; Alexandra Cloutet; Ahish Chitneni; Giustino Varrassi; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-11

5.  The Median Effective Dose and Bispectral Index of Remimazolam Tosilate for Anesthesia Induction in Elderly Patients: An Up-and-Down Sequential Allocation Trial.

Authors:  Miao Liu; Yuan Sun; Lingxue Zhou; Kunpeng Feng; Tianlong Wang; Xuexin Feng
Journal:  Clin Interv Aging       Date:  2022-05-20       Impact factor: 3.829

6.  The effect of flumazenil on the recovery time of dental patients sedated with diazepam.

Authors:  E R Young; S H Kestenberg; C B Toal
Journal:  Anesth Prog       Date:  1989 Mar-Apr

Review 7.  Pharmacokinetic implications for the clinical use of propofol.

Authors:  J Kanto; E Gepts
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

8.  Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788.

Authors:  U Klotz; T Duka; R Dorow; A Doenicke
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

Review 9.  Midazolam. A review of its pharmacological properties and therapeutic use.

Authors:  J W Dundee; N J Halliday; K W Harper; R N Brogden
Journal:  Drugs       Date:  1984-12       Impact factor: 9.546

10.  Hypotension after general anesthesia induction using remimazolam in geriatric patients: Protocol for a double-blind randomized controlled trial.

Authors:  Masashi Yokose; Ryuki Takaki; Takahiro Mihara; Yusuke Saigusa; Natsuhiro Yamamoto; Kenichi Masui; Takahisa Goto
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.